Saltar al contenido
Merck

L6545

Sigma-Aldrich

Letrozole

≥98% (HPLC), powder, non-steroidal aromatase inhibitor

Sinónimos:

4,4′-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C17H11N5
Número de CAS:
Peso molecular:
285.30
MDL number:
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77

product name

Letrozole, ≥98% (HPLC)

Quality Level

assay

≥98% (HPLC)

form

powder

color

white to off-white

solubility

DMSO: >50 mg/mL

originator

Novartis

storage temp.

2-8°C

SMILES string

N#CC(C=C1)=CC=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3

InChI

1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H

InChI key

HPJKCIUCZWXJDR-UHFFFAOYSA-N

Gene Information

human ... CYP19A1(1588)

¿Está buscando productos similares? Visita Guía de comparación de productos

Application

Letrozole has been used:
  • in organoid growth assay to determine its inhibitory capacity(48)
  • to investigate steroid receptor coactivator-1 (SRC-1) mediated endogenous estrogen regulation of hippocampal PSD-95(49)
  • to determine its effects on tumor-induced hyperalgesia(50)
  • for hormonal manipulation in rats(51)
  • to study its effects on lipocalin-2 (Lcn2)(52)
  • to determine its effects on mechanical hyperalgesia and aromatase expression(53)

Biochem/physiol Actions

Letrozole acts as an adjuvant agent and is used to treat breast cancer.
Letrozole is a third generation nonsteroidal aromatase inhibitor. It is a competitive inhibitor of the aromatase enzyme system and thus inhibits the conversion of androgens to estrogens. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazard

signalword

Warning

Hazard Classifications

Repr. 2 - STOT RE 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Natalia Lagunas et al.
Frontiers in neuroanatomy, 16, 902218-902218 (2022-07-12)
Sex steroid hormones, such as androgens and estrogens, are known to exert organizational action at perinatal periods and activational effects during adulthood on the brain and peripheral tissues. These organizational effects are essential for the establishment of biological axes responsible
Bianca Posocco et al.
PloS one, 15(2), e0228822-e0228822 (2020-02-08)
A novel LC-MS/MS method was developed for the quantification of the new cyclin dependent kinase inhibitors (CDKIs) palbociclib and ribociclib and the aromatase inhibitor letrozole used in combinatory regimen. The proposed method is appropriate to be applied in clinical practice
Drugs for Pregnant and Lactating Women E-Book (2009)
Zahra Shaaban et al.
Iranian journal of basic medical sciences, 25(1), 110-120 (2022-06-04)
Despite prevalence of polycystic ovary syndrome (PCOS) among childbearing women and development of many animal models for this syndrome, information on its etiology is still scarce. The intrauterine hyperandrogenic environment may underlie changes at the level of hypothalamus, pituitary, ovary
Lijun Tan et al.
Cancers, 14(19) (2022-10-15)
Antiestrogen therapy (AET) is an alternative to cytotoxic chemotherapy for recurrent ovarian cancer, yet the often short duration of response suggests mechanisms of resistance. We previously demonstrated that tumor microenvironment interleukin-6/leukemia inhibitory factor (IL6/LIF) cytokines induce tumor cell JAK-STAT signaling

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico